Provided by Tiger Fintech (Singapore) Pte. Ltd.

Alnylam Pharmaceuticals

251.15
-7.2000-2.79%
Post-market: 251.150.00000.00%17:28 EDT
Volume:656.36K
Turnover:166.30M
Market Cap:32.75B
PE:-119.69
High:260.00
Open:259.92
Low:250.35
Close:258.35
Loading ...

Alnylam Pharmaceuticals Q1 Adj. EPS $(0.01) Beats $(1.03) Estimate, Sales $594.19M Beat $585.82M Estimate

Benzinga
·
01 May

BRIEF-Alnylam Pharmaceuticals Q1 Adjusted EPS USD -0.01 Vs. IBES Estimate USD -1.03

Reuters
·
01 May

Alnylam Pharmaceuticals Q1 Basic EPS USD -0.44

THOMSON REUTERS
·
01 May

Alnylam Pharmaceuticals Q1 Adjusted Operating Income USD 74.789 Million VS. Ibes Estimate USD -105.3 Million

THOMSON REUTERS
·
01 May

Alnylam Pharmaceuticals Inc - Reiterates 2025 Guidance

THOMSON REUTERS
·
01 May

Alnylam Pharmaceuticals Q1 Net Product Revenue USD 594.189 Million

THOMSON REUTERS
·
01 May

Alnylam Pharmaceuticals Q1 Operating Income USD 18.077 Million

THOMSON REUTERS
·
01 May

Alnylam Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Period Progress

Business Wire
·
01 May

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
01 May

Seeking Clues to Alnylam (ALNY) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics

Zacks
·
29 Apr

Analysts Are Bullish on These Healthcare Stocks: Axsome Therapeutics (AXSM), Alnylam Pharma (ALNY)

TIPRANKS
·
29 Apr

Alnylam's Transthyretin Amyloidosis Drug Gets Positive Opinion From European Medicines Agency

MT Newswires Live
·
28 Apr

BRIEF-Alnylam Receives Positive CHMP Opinion For Vutrisiran For The Treatment Of Attr Amyloidosis With Cardiomyopathy

Reuters
·
28 Apr

Alnylam Pharmaceuticals Inc - European Commission Decision on Vutrisiran Expected June 2025

THOMSON REUTERS
·
28 Apr

Alnylam Receives Positive CHMP Opinion for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy

Business Wire
·
28 Apr

Earnings Preview: Alnylam Pharmaceuticals (ALNY) Q1 Earnings Expected to Decline

Zacks
·
24 Apr

U.S. RESEARCH ROUNDUP-Lowe's, Netflix, Vulcan Materials

Reuters
·
21 Apr

Alnylam Pharmaceuticals Inc : Jefferies Raises Target Price to $329 From $325

THOMSON REUTERS
·
21 Apr

BofA Adjusts Price Target on Alnylam Pharmaceuticals to $328 From $325, Keeps Buy Rating

MT Newswires Live
·
17 Apr

Press Release: Alnylam to Webcast Conference Call Discussing First Quarter 2025 Financial Results

Dow Jones
·
17 Apr